1. Introduction {#sec1-pharmaceuticals-13-00059}
===============

The resurgence of drug-resistant infectious diseases, as well as cancers, propels the scientific community to seek alternative medicine. This double burden is indeed a serious public health-threatening worldwide \[[@B1-pharmaceuticals-13-00059]\]. As part of the implementation of the Global Action Plan on antimicrobial resistance (AMR), the World Health Organization (WHO) caught up with a list of priority antibiotic-resistant pathogens to guide research into and the discovery and development of new therapeutic agents. Some bacteria, listed as a critical priority, are the members of the group named ESKAPEE (*Enterococcus* spp., *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter* spp., and *Escherichia coli*) \[[@B2-pharmaceuticals-13-00059],[@B3-pharmaceuticals-13-00059]\]. Yet, alternative strains like *Salmonella* species are also of clinical concern. Botanicals are broadly recognized as some of the most prolific sources of leads for the development of new drug candidates. They cover a large spectrum of therapeutic uses with a great diversity of chemical structures. The scientific community still considers exploring medicinal plants for new drug discovery. The application of molecular, analytical, and computational techniques has raised the availability of novel compounds that can be handily isolated from natural sources \[[@B4-pharmaceuticals-13-00059],[@B5-pharmaceuticals-13-00059]\]. Many species memberships to the genus *Echinops* are used in traditional medicine, primarily in Africa and Asia, to treat various ailments including infectious and respiratory diseases, inflammation, and to relieve pain. They are also claimed to have aphrodisiac properties, to fasten expulsion of the placenta, and to act on the kidney for the elimination of renal stones. More than 151 compounds have been isolated from the *Echinops* genus including thiophenes, terpenes, flavonoids, and other phenolic compounds, phenylpropanoids, alkaloids, and lipids \[[@B6-pharmaceuticals-13-00059]\]. Varied extracts, isolated compounds, and essential oils from members of this genus were found to exert multiple biological properties including anti-infective, antiproliferative, antioxidant, and anti-inflammatory \[[@B6-pharmaceuticals-13-00059]\]. However, several species belonging to this genus are claimed to have traditional medicinal uses but their biological effect not yet been investigated. It is the case of the member examined in the present study namely *Echinops lanceolatus*.

*Echinops lanceolatus* Mattf. (Asteraceae) is a native plant to Cameroon, Central African Republic, and Nigeria \[[@B7-pharmaceuticals-13-00059]\]. *E. lanceolatus* is a spiny perennial herb, chamaephytes, with marcescent leaves. It is a much-branched herb with stout stems 2--3 ft. high from a woody stock. Florets are blue or white in spherical heads up to 2 in. across. This plant species is widely distributed in open grassland including West Tropical Africa \[[@B7-pharmaceuticals-13-00059],[@B8-pharmaceuticals-13-00059]\]. To the best of our knowledge, no biological activities, nor phytochemical studies have been reported on this plant species. In the present investigation, as part of our continuing search for potent therapeutic agents from natural sources, we assessed their antibacterial and antiproliferative potential. Assays were performed against the ESKAPEE group's bacteria and *Salmonella enterica*, and human tumor cell lines (HepG2, HeLa, HT-29, and A549). The ultra-performance liquid chromatography (UPLC) coupled to electrospray ionization tandem mass spectrometry (ESI--MS/MS) analysis was applied for the identification of the potential bioactive chemical components of the ethyl acetate fraction (EL-EA), the most active extract. Compounds were tentatively identified based on the comparison of their ESI-MS^2^ data with the corresponding standards and fragmentation pathways from databases (ChemSpider, HMDB, PubChem, mzCloud, and mzVault) and/or data available in the literature. To the best of our knowledge, the present study reports for the first time the biological properties of *E. lanceolatus* and their phytochemical profile. This, therefore, provides a baseline for thorough investigations for the isolation, purification, and development of potent phytomedicine against the double burden of infectious diseases and tumors.

2. Results {#sec2-pharmaceuticals-13-00059}
==========

2.1. Antibacterial Potential {#sec2dot1-pharmaceuticals-13-00059}
----------------------------

Results of bacterial susceptibility testing to *E. lanceolatus* extracts are summarized in [Table 1](#pharmaceuticals-13-00059-t001){ref-type="table"}. Methanolic extract (EL-MeOH) and fractions depicted selective inhibitory effects depending on the studied bacteria strain, with minimal inhibitory concentrations (MICs) varying from 256 to 1024 µg/mL. The lowest MIC value of 256 µg/mL was recorded with EL-EA against *S. enterica*. EL-EA exhibited the highest spectrum of inhibition, acting against 6/8 of studied bacteria, followed by the dichloromethane (EL-DCM) fraction (5/8). EL-MeOH and other fractions (*n*-hexane and *n*-butanol) exerted the activity on 4/8 bacteria strains. Interestingly, EL-MeOH, and all subsequent partition fractions, prevented the growth of *S. enterica*, *E. cloacae*, and *S. aureus*. A bactericidal effect (minimal bactericidal concentration (MBC) = 1024 µg/mL) was recorded with EL-EA on *S. aureus*.

2.2. The Antiproliferative Potential of E. lanceolatus {#sec2dot2-pharmaceuticals-13-00059}
------------------------------------------------------

The percentage of tumor cell growth inhibition of studied samples is shown in [Figure 1](#pharmaceuticals-13-00059-f001){ref-type="fig"}. At a fixed concentration of 100 µg/mL, EL-MeOH and fractions from *E. lanceolatus* displayed antiproliferative activity depending on studied cells. EL-EA was found to be the most potent, displaying significant inhibition of 72% and 71% on HepG2 and A549, respectively.

Furthermore, a concentration-dependent effect of EL-EA (tested at concentrations ranging from 0.82 to 200 µg/mL) was studied on HepG2, A549, HeLa, and HT-29 cell lines for 48 h. The results revealed a dose-dependent inhibition of tumor cell growth ([Figure 2](#pharmaceuticals-13-00059-f002){ref-type="fig"}). The IC~50~ values ranged from 8.27 to 76.91 µg/mL. The lowest IC~50~ value (significant activity) of 8.27 µg/mL recorded on A549.

2.3. UPLC--ESI--MS/MS Analysis of EL-EA Fraction {#sec2dot3-pharmaceuticals-13-00059}
------------------------------------------------

To explore the potential bioactive compounds in the EL-EA fraction, which may be responsible for the recorded biological activities, a study of the EL-EA fraction was conducted based on UPLC--ESI--MS/MS in the negative ion mode. The analysis led to the detection of several peaks in that fraction, of which 32 compounds were identified with high-resolution MS and MS/MS data ([Figure 3](#pharmaceuticals-13-00059-f003){ref-type="fig"}). Compounds corresponding to Peaks 1 to 24 were identified by comparison of the mass spectra with the available standards from databases (ChemSpider, mzCloud, mzVault, HDMB, and PubChem) and the literature data; identification of Peaks 25 to 32 was only based on available standards from databases. The retention times (Rt), molecular formula, and MS^2^ data are condensed in [Table 2](#pharmaceuticals-13-00059-t002){ref-type="table"}. Some major peaks found between 9 and 10, 13 and 14, 17 and 18, 19 and 20, 20 and 21, 22 and 23, 25 and 26, 26 and 27, 27 and 28, 29 and 30, 30 and 31, and after Peak 31 ([Figure 1](#pharmaceuticals-13-00059-f001){ref-type="fig"}) were not identified. Subject to further studies, we can hypothesize that the corresponding unidentified compounds may be new. The phytochemicals successfully identified were mainly phenolic acids, polyphenols (flavonoids and lignan), organic acids, and fatty acids, as detailed below. The chemical structures of some well-known identified compounds of biological importance are shown in [Figure 4](#pharmaceuticals-13-00059-f004){ref-type="fig"}.

### 2.3.1. Phenolic Acids {#sec2dot3dot1-pharmaceuticals-13-00059}

Peak 2 was identified as d-(-)-quinic acid, which showed an \[M-H\]^−^ ion at *m/z* 191.0551. Identified quinic derivatives (or conjugates) included 5-coumaroylquinic acid, which showed an \[M-H\]^−^ ion at *m/z* 337.0924 (Peak 12), a 5-feruloyl quinic acid \[M-H\]^−^ ion at *m/z* 367.1027 (Peak 13), a dicaffeoylquinicacid (DCQ) isomer 1 \[M-H\]^−^ ion at *m/z* 515.1187 (Peak 14), a DCQ isomer 2 \[M-H\]^−^ ion at *m/z* 515.1186 (Peak 15), and a DCQ isomers 3 and 4 \[M-H\]^−^ ion at *m/z* 515.1189 (Peaks 16 and 17, respectively). Other phenolic acids included a dihydroxybenzoic acid \[M-H\]^−^ ion at *m/z* 153.0181 (Peak 3), a hydroxy-methoxy-benzoic acid isomers 1 and 2 \[M-H\]^−^ ion at *m/z* 167.0338 (Peaks 4 and 6, respectively), and a 3-hydroxybenzoic acid \[M-H\]^−^ ion at *m/z* 137.0231 (Peak 11). The identified cinnamic acid derivatives comprised dihydroxycinnamic acid isomers 1 (Peak 5, \[M-H\]^−^ ion at *m/z* 179.0339) and 2 (Peak 7, \[M-H\]^−^ ion at *m/z* 179.0338), and a coumaric acid isomers 1 and 2 \[M-H\]^−^ ion at *m/z* 163.0389 (Peaks 8 and 9, respectively). Peak 21 was identified as coniferyl aldehyde, which showed an \[M-H\]^−^ ion at *m/z* 177.0546.

### 2.3.2. Polyphenols {#sec2dot3dot2-pharmaceuticals-13-00059}

#### Flavonoids

Peak 18 was identified as dihydrokaempferol (\[M-H\]^−^ ion at *m/z* 287.0556), a flavanonol. Peaks 19 and 22 were two flavanone glycosides, namely a naringenin-7-*O*-glucoside (prunin) (\[M-H\]^−^ ion at *m/z* 433.1134) and a naringin (\[M-H\]^−^ ion at *m/z* 579.1503), respectively. Peak 24 was identified as an apigenin (\[M-H\]^−^ ion at *m/z* 269.0451). Two other memberships of apigenin family have been also detected, corresponding to Peak 20 (apigenin-7-*O*-β-[d]{.smallcaps}-glucoside (cosmosiin or apigetrin), \[M-H\]^−^ ion at *m/z* 431.0977) and Peak 23 (rhoifolin, \[M-H\]^−^ ion at *m/z* 577.1346).

#### Lignan

Peak 26 was identified as (-)-secoisolariciresinol, which showed an \[M-H\]^−^ ion at *m/z* 361.0818.

### 2.3.3. Organic Acids and Fatty Acids {#sec2dot3dot3-pharmaceuticals-13-00059}

The identified organic acids included carboxylic acids namely a succinic acid \[M-H\]^−^ ion at *m/z* 117.0180 (Peak 1), a nonanedioic acid \[M-H\]^−^ ion at *m/z* 187.0965 (Peak 10), and a cyclandelate \[M-H\]^−^ ion at *m/z* 275.1647 (Peak 29). The fatty acids found were a (-)-pinellic acid \[M-H\]^−^ ion at *m/z* 329.2328 (Peak 25), polyunsaturated fatty acids including a 13-KODE (13-Keto-9Z,11E-octadecadienoic acid) \[M-H\]^−^ ion at *m/z* 293.21 (Peak 27), a 13-HODE (13S-hydroxyoctadecadienoic acid) \[M-H\]^−^ ion at *m/z* 293.2117 (Peak 28), and an alpha-linolenic acid \[M-H\]^−^ ion at *m/z* 277.2166 (Peak 30, tentatively). Peak 31 was tentatively identified as an ethyl myristate \[M-H\]^−^ ion at *m/z* 255.2324, a long-chain saturated fatty acid. Peak 32 was tentatively identified as an oleic acid \[M-H\]^−^ ion at *m/z* 281.2479, a C18 monounsaturated fatty acid.

3. Discussion {#sec3-pharmaceuticals-13-00059}
=============

Our study included the ESKAPEE group's bacteria and *S. enterica*. These bacteria are known to express high resistance to traditional antibiotics \[[@B3-pharmaceuticals-13-00059],[@B22-pharmaceuticals-13-00059]\]. The WHO \[[@B2-pharmaceuticals-13-00059]\], in the context of research for efficient therapeutic agents against AMR, gave priority to these bacteria of clinical concern for antibacterial research. These, therefore, represent the good models in the search of alternative medicine to combat drug resistance. The antibiotic resistance profile of studied bacteria was ascertained during preliminary investigations (data not shown). Medicinal plant extracts are routinely classified as highly active if the MIC \< 100 μg/mL, moderately active when 100 ≤ MIC ≤ 625 μg/mL, and weakly active if MIC ≥ 625 µg/mL \[[@B23-pharmaceuticals-13-00059]\]. According to these interpretive criteria, it can be deduced that EL-MeOH and the subsequent partition fractions displayed weak to moderate antibacterial activities based on MIC values obtained. The moderate activity was recorded with EL-EA against *S. enterica* (MIC = 256 µg/mL), *E. cloacae,* and *S. aureus* (MIC = 512 µg/mL); EL-DCM against *S. aureus* (MIC = 512 µg/mL); EL-Hex and EL-BuOH fractions against *S. enterica* and *E. coli* (MIC = 512 µg/mL), respectively ([Table 1](#pharmaceuticals-13-00059-t001){ref-type="table"}). The EL-MeOH, as a complex mixture of chemical components, was less active than derived fractions. These indicate that partitioning by successive depletion enhances the biological activity of *E. lanceolatus*. All fractions were found effective against *S. enterica* and *S. aureus*. These bacteria are common food-borne pathogens causing gastrointestinal (GIT) troubles \[[@B24-pharmaceuticals-13-00059]\]. The present study underscores evidence of the traditional use of *Echinops* L. in the treatment of GIT troubles. Most of the studied bacterial strains were Gram-negative. The latter is found most resistant compared to their counter-part Gram-positive ones, owed to the presence of an outer membrane. The outer membrane gives Gram-negative bacteria an increased ability to reduce the penetration of antibacterial molecules across the membrane, leading to intrinsic resistance to many molecules including therapeutic agents \[[@B25-pharmaceuticals-13-00059],[@B26-pharmaceuticals-13-00059]\]. The differences of sensitivity recorded for the same extract with different bacteria strains could be due to intrinsic differences in the chemical composition of the bacterial cell wall \[[@B26-pharmaceuticals-13-00059]\]. Otherwise, the differences obtained for the same bacterium and the different fractions suggest the qualitative and quantitative differences in antibacterial active principles or different action mechanisms of biologically active components.

The cytotoxicity of a plant extract on cancer cell lines is considered significant or strong when IC~50~ \< 20 µg/mL, moderate if 20 µg/mL \< IC~50~ \< 50 µg/mL, low if 50 µg/mL \< IC~50~ \< 200 µg/mL, and no cytotoxicity if IC~50~ \> 200 µg/mL \[[@B27-pharmaceuticals-13-00059]\]. Based on these cut-off points, the EL-EA fraction depicted strong cytotoxicity against adenocarcinomic human alveolar basal epithelial cells A549 (IC~50~ = 8.27 µg/mL). In addition, the same fraction showed moderate cytotoxicity on HeLa (IC~50~ = 28.27 µg/mL). As previously observed with antibacterial activities, EL-EA displayed noteworthy anticancer potential, suggesting their potential use in the fighting against the double burden of infectious diseases and cancers. To the best of our knowledge, the present investigation reports for the first time the antibacterial activity and antiproliferative potential of *E. lanceolatus*. However, some species of the genus *Echinops* (Asteraceae), such as *Echinops giganteus* and *Echinops grijsii*, are well known to have significant anti-tumor and anti-infective effects \[[@B6-pharmaceuticals-13-00059]\]. The present study provides additional information on the antibacterial and cytotoxic properties of the aerial parts of *E. lanceolatus*, membership of the *Echinops* genus and Asteraceae family. The biological properties of *E. lanceolatus,* and particularly the EL-EA fraction recorded, could be attributed to the presence of structurally diverse secondary metabolites. Several phytochemicals have displayed functional activities that imply they could be responsible for a significant role in preventing a broad range of chronic diseases. However, the bioactivity of a plant extract does not depend exclusively on the presence of secondary metabolites. Indeed, the quantity, the quality, the type of extraction solvent, and possible interactions between the different constituents are some factors, which can also influence the activities \[[@B28-pharmaceuticals-13-00059],[@B29-pharmaceuticals-13-00059],[@B30-pharmaceuticals-13-00059],[@B31-pharmaceuticals-13-00059],[@B32-pharmaceuticals-13-00059]\]. The UPLC--ESI--MS/MS analysis of EL-EA revealed the presence of many compounds of which 32 have been identified, as shown in [Table 2](#pharmaceuticals-13-00059-t002){ref-type="table"}. The identified chemical compounds were mainly phenolic acids, flavonoids, lignan, organic acids, and fatty acids. The biological effects of these groups of compounds are no longer to be demonstrated. The bioactivity of identified compounds has been widely reported in the literature.

Some of the identified compounds including quinic acid, apigenin, apigenin-7-*O*-glucoside, kaempferol, and dicaffeoylquinic acid are common to members of the *Echinops* genus and Asteraceae family \[[@B6-pharmaceuticals-13-00059]\]. Several studies documented on biological activities (including antimicrobial and antiproliferative properties) of organic acids (succinic and dihydrobenzoic acids) \[[@B33-pharmaceuticals-13-00059],[@B34-pharmaceuticals-13-00059],[@B35-pharmaceuticals-13-00059],[@B36-pharmaceuticals-13-00059]\] and phenolic compounds (cinnamic acid derivatives, quinic acid and derivatives) \[[@B37-pharmaceuticals-13-00059],[@B38-pharmaceuticals-13-00059],[@B39-pharmaceuticals-13-00059],[@B40-pharmaceuticals-13-00059],[@B41-pharmaceuticals-13-00059],[@B42-pharmaceuticals-13-00059]\] identified in the present work. The flavonoids identified are not to be outdone. Flavonoids represent the largest group of naturally occurring polyphenols. They are common plant secondary metabolites widely used in phytomedicine to cure a wide range of ailments. Some are well-known antiproliferative phytochemicals such as dihydrokaempferol \[[@B43-pharmaceuticals-13-00059]\], flavanones glycosides (naringenin-7-*O*-glucoside, apigenin-7-*O*-β-[d]{.smallcaps}-glucoside, and naringin) \[[@B44-pharmaceuticals-13-00059],[@B45-pharmaceuticals-13-00059],[@B46-pharmaceuticals-13-00059],[@B47-pharmaceuticals-13-00059],[@B48-pharmaceuticals-13-00059]\]. Apigenin is another flavonoid class compound reported to exhibit several biological functions such as antibacterial, antiviral, anti-inflammatory, and antioxidant activities \[[@B49-pharmaceuticals-13-00059],[@B50-pharmaceuticals-13-00059]\]. A well-known member of the apigenin family, with substantial biological properties, is the tri-substituted flavone rhoifolin \[[@B51-pharmaceuticals-13-00059]\], also identified in the present investigation. Other compounds identified including the phenylpropanoid coniferyl aldehyde \[[@B52-pharmaceuticals-13-00059]\], the dibenzyl butanediol lignan (-)-secoisolariciresinol \[[@B53-pharmaceuticals-13-00059],[@B54-pharmaceuticals-13-00059]\], and fatty acids \[[@B55-pharmaceuticals-13-00059]\] have been revealed to possess valuable biological benefit against microbes and malign cells.

The biological activities of secondary metabolites identified in the present study underscore the correlation of the presence of these phytochemicals in *E. lanceolatus* and their antimicrobial and antiproliferative potential obtained against studied drug-resistant bacteria and human tumor cell lines (HeLa, A549, HepG2, HT-29), respectively. Each constituent could act by interacting with other constituents of the mixture, leading to the recorded activities. However, we can also hypothesize about the individual action of some compounds. The present study gives evidence of *E. lanceolatus* as a plant of pharmaceutical importance, a valuable source of biologically active compounds. Thorough investigations will allow the isolation and purification of each component along with an evaluation of their biological properties and action mechanisms.

4. Materials and Methods {#sec4-pharmaceuticals-13-00059}
========================

4.1. Chemicals and Reagents {#sec4dot1-pharmaceuticals-13-00059}
---------------------------

Trypticase Soy Agar (TSA) and Trypticase Soy Broth (TSB) (Qingdao Hope Bio-Technology, Qingdao, China) were used for bacteria culture. *para*-Iodonitrotetrazolium chloride (INT 98%, Macklin, Shanghai, China) served as a bacterial growth indicator. Dimethyl sulfoxide (DMSO ≥99.0%) obtained from Sinopharm Chemical Reagent (Shanghai, China) was used to dissolve extracts. Streptomycin (purity \>98%, Abmole Biosciences, Houston, TX, USA) was used as the positive control for bacterial susceptibility testing. Dulbecco's Modified Eagle Medium (DMEM, Gibco, Beijing, China), Minimum Essential Medium Eagle (MEM, Hyclone, Logan, UT, USA), McCoy's 5A (Boster Biological Technology Co., Ltd., Pleasanton, CA, USA), and Ham's F12 K (Procell Life Science & Technology Co., Ltd., Wuhan, China) were used for cancer cells culture. Other reagents for cell culture including fetal bovine serum (FBS), Sulforhodamine B (SRB), glutamine, and penicillin were obtained from Sigma-Aldrich (St. Louis, MO, USA).

4.2. Plant Material {#sec4dot2-pharmaceuticals-13-00059}
-------------------

The aerial parts of *Echinops lanceolatus* Matt F. (Asteraceae) were collected in Bangangté (West Region, Cameroon), coordinates (5.1444° N, 10.5240° E), in July 2018. The fresh plant was cleaned with water, cut into fine parts, and then air-dried away from direct sunlight. Next, the air-dried plant was crushed and the resulting powder packed for further experiments. The plant sample was identified and authenticated at the National Herbarium of Cameroon (HNC, Yaoundé, Cameroon) with the kind assistance of M. Eric Ngansop (Taxonomist, HNC), where a voucher specimen was lodged under a reference number (14148SRF-CAM and 35113/HNC).

4.3. Extraction Procedure {#sec4dot3-pharmaceuticals-13-00059}
-------------------------

Air-dried powder (100 g) of plant sample was macerated into methanol (MeOH) for 24 h, followed by ultrasound-assisted extraction (KQ-500DE, Kunshan Ultrasonic Instrument Co., Ltd.) for 30 min. The mixture was filtered using Whatman paper grade 1. The same procedure was repeated twice with the remaining residue. The overall filtrate was evaporated under vacuum in a rotary evaporator at reducing pressure and temperature (below 45 °C) to yield 7.5 g of an oily dark extract. The partitioning was carried out according to the scheme previously described \[[@B56-pharmaceuticals-13-00059]\]. In brief, MeOH extract was suspended in deionized water to make a 95% aqueous solution. Afterward, a successive depletion was performed using solvents of increasing polarity including *n*-hexane, dichloromethane (DCM), ethyl acetate (EA), *n*-butanol (*n*-BuOH), and finally water (H~2~O), to afford fractions. Corresponding fractions were evaporated *in vacuo* to yield the residues of 0.84 g, 0.56 g, 0.35 g, 1.85 g, and 2.3 g, respectively. MeOH extract and fractions were kept at 4 °C for future uses.

4.4. UPLC--ESI--MS/MS Analysis {#sec4dot4-pharmaceuticals-13-00059}
------------------------------

A Q Exactive Orbitrap^®^ LC-MS/MS (Thermo Fisher Scientific, San Jose, CA, USA) mass spectrometer coupled with a Vanquish UPLC system (Thermo Fisher Scientific, San Jose, CA, USA) was employed for the LC-MS analysis, which was equipped with an ESI source. The separation of the EL-EA fraction was acquired with a Hypersil Gold column (C18) column (150 × 2.1 mm, 5 μm) at 25 °C. The injection volume of the sample was 1 µL. Scan range *m/z* 70-1050; ESI Spray Voltage: 3.2 kV; Sheath gas flow rate: 35 (arbitrary units); Aux Gas flow rate: 10 (arbitrary units); Capillary Temp: 320 °C. Polarity: negative; MS/MS data-dependent scans. The mobile phase B and the used gradient condition are shown in [Table 3](#pharmaceuticals-13-00059-t003){ref-type="table"}.

Compounds in EL-EA were identified by comparing the retention time, parent ion, and mass fragments with available standards in databases (ChemSpider, mzCloud, mzVault, HMDB, and PubChem) and/or literature data \[[@B9-pharmaceuticals-13-00059],[@B10-pharmaceuticals-13-00059],[@B11-pharmaceuticals-13-00059],[@B12-pharmaceuticals-13-00059],[@B13-pharmaceuticals-13-00059],[@B14-pharmaceuticals-13-00059],[@B15-pharmaceuticals-13-00059],[@B16-pharmaceuticals-13-00059],[@B17-pharmaceuticals-13-00059],[@B18-pharmaceuticals-13-00059],[@B19-pharmaceuticals-13-00059],[@B20-pharmaceuticals-13-00059],[@B21-pharmaceuticals-13-00059]\].

4.5. Antibacterial Assay {#sec4dot5-pharmaceuticals-13-00059}
------------------------

### 4.5.1. Bacterial Strains {#sec4dot5dot1-pharmaceuticals-13-00059}

Eight drug-resistant bacterial strains were examined for their sensitivity to crude MeOH extract and fractions. They were obtained from CCTCC (China Center for Type Culture Collection), CMCC (Center for Medical Culture Collection), and ATCC (American Type Culture Collection). These strains included two Gram-positive (*Enterococcus faecalis* ATCC29212 and *Staphylococcus aureus* CCTCC AB91093) and six Gram-negative bacteria (*Acinetobacter baumannii* ATCC19606, *Enterobacter cloacae* ATCC700323, *Escherichia coli* CCTCC AB93154, *Klebsiella pneumoniae* CMCC(B)46117, *Pseudomonas aeruginosa* ATCC9027, and *Salmonella enterica* CCTCC AB94018). The WHO \[[@B2-pharmaceuticals-13-00059]\] has classified the selected strains as priorities in the research for antibacterial agents.

The studied bacteria were maintained on agar slant at 4 °C and each bacteria strain was subcultured (activation) at 37 °C for 18--24 h on fresh appropriate agar plates 24 h before any antibacterial assay. Trypticase Soy Agar (TSA) was used for the activation of studied microorganisms, whereas Trypticase Soy Broth (TSB) was taken on for MIC and MBC determinations. Bacteria inoculum was initially prepared at McFarland 0.5, equivalent to 1.5 × 10^8^ CFU/mL.

### 4.5.2. INT Colorimetric Assay for MIC and MBC Determinations {#sec4dot5dot2-pharmaceuticals-13-00059}

Bacterial susceptibility testing was performed by broth microdilution in 96-well microplates, using *para*-iodonitrotetrazolium chloride (INT) as a bacterial growth indicator. INT acts as an electron acceptor and reacts with dehydrogenases released by bacteria during the kinetic growth to form an insoluble pink-colored formazan. The assay was carried out according to the previously described protocol \[[@B29-pharmaceuticals-13-00059],[@B30-pharmaceuticals-13-00059],[@B31-pharmaceuticals-13-00059],[@B32-pharmaceuticals-13-00059]\]. Briefly, the extracts were dissolved beforehand in the DMSO/TSB mixture. The final concentration of DMSO was less than 2.5%; this concentration is innocuous to bacterial growth. One hundred microliters of the solution were then added to the same volume of TSB in the wells of 96-well microplates followed by a two-fold serial dilution. The next step consisted of adding 100 μL of bacterial suspension (1.5 × 10^6^ CFU/mL) prepared in TSB. The plates were covered with a sterile plate sealer, then mixed by shaking for 10 min, and finally incubated at 37 °C for 18 h. The experiment was done in triplicate and repeated thrice. MIC was considered as the lowest concentration of the plant extract that prevented the visible growth of the tested bacteria. The growth of bacterial cells in each of the wells was confirmed by color change after the addition of 40 µL of INT 0.02% (w/v). In the absence of bacterial growth inhibition, the INT changed from clear to pink. Wells with DMSO alone as well as wells without any treatment were used as negative controls. Streptomycin was used as a positive control.

The MBC was determined after subculture of 50 µL (of wells content corresponding to values ≥ MIC) in 150 µL of TSB contained in new 96-well microplates, followed by incubation (37 °C) for 48 h. Then, INT was used as the abovementioned to reveal bacterial growth. The MBC was considered as the lowest concentration of the sample, which prevents a color change after the addition of INT, corresponding to the total killing effect of bacteria cells \[[@B29-pharmaceuticals-13-00059],[@B30-pharmaceuticals-13-00059],[@B31-pharmaceuticals-13-00059],[@B32-pharmaceuticals-13-00059]\].

4.6. In Vitro Antiproliferative Assays {#sec4dot6-pharmaceuticals-13-00059}
--------------------------------------

Antiproliferative properties of *E. lanceolatus* extracts were performed on four human tumor cell lines provided by the China Center for Type Culture Collection (CCTCC). These included HepG2 (human liver cancer cell line), HeLa (cervical cancer cells), HT-29 (human colon cancer cell line), and A549 (adenocarcinomic human alveolar basal epithelial cells). Cells were maintained in an adequate medium: Dulbecco's Modified Eagle Medium (DMEM) for HepG2, Minimum Essential Medium Eagle (MEM) for HeLa, McCoy's 5A for HT-29, and Ham's F12 K for A549. Each culture medium was supplemented with 10% FBS, glutamine (2 mM) and 1% penicillin (100 U/mL)-streptomycin (100 µg/mL). Moreover, the cell lines were sub-cultured twice a week and incubated in a moistened atmosphere at 37 °C with 5% CO~2~ and 90% relative humidity. Hematocytometer and phase-contrast microscopy were used for the counting of viable cells. The cells at the exponential growth phase (beyond 80% confluence) were exploited for cell antiproliferative testing \[[@B57-pharmaceuticals-13-00059]\].

SRB colorimetric assay was used to investigate the antiproliferative properties of the plant extracts on the aforementioned cell lines, according to the previously described protocol \[[@B57-pharmaceuticals-13-00059],[@B58-pharmaceuticals-13-00059]\]. IC~50~ was determined and considered as the concentration of plant extract required to inhibit 50% of the cell proliferation and was calculated by plotting the percentage survival versus the concentrations, using GraphPad Prism 8.0.1. Each test sample solution was performed in triplicate, in a single experiment.

4.7. Statistical Analysis {#sec4dot7-pharmaceuticals-13-00059}
-------------------------

All tests were done in triplicate and the data obtained from antiproliferative assays were analyzed using GraphPad Prism 8.0.1 software (GraphPad., San Diego, CA, USA).

5. Conclusions {#sec5-pharmaceuticals-13-00059}
==============

Our findings revealed the antibacterial potential and antiproliferative activities of *E. lanceolatus* crude methanolic extract and subsequent partition fractions (*n*-hexane, dichloromethane, ethyl acetate, and *n*-butanol). The ethyl acetate fraction was found to be the most effective one, and 32 phytochemicals have been identified in this fraction, of which quinic acid and derivatives, dihydrokaempferol, naringenin-7-*O*-glucoside, apigenin-7-*O*-glucoside, naringin, apigenin, rhoifolin, coniferyl aldehyde, and secoisolariciresinol are well documented for their antimicrobial and antiproliferative properties. These make substantial evidence to consider *E. lanceolatus* as a plant of biological importance, a valuable source for anti-infective and antitumor agents.
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![Percentage of cell growth inhibition of *E. lanceolatus* extracts. Data are expressed as mean ± SEM, *p* \< 0.05.](pharmaceuticals-13-00059-g001){#pharmaceuticals-13-00059-f001}

![Concentration-dependent antiproliferative activities of EL-EA against (**a**) HeLa, (**b**) HepG2, (**c**) HT-29, and (**d**) A549 human tumor cell lines. Cells incubated with extract for 48 h. IC~50~: half-maximal inhibitory concentration. EL-EA: *E. lanceolatus* ethyl acetate fraction. HepG2 (human liver cancer cell line), HeLa (cervical cancer cells), HT-29 (human colon cancer cell line), and A549 (adenocarcinomic human alveolar basal epithelial cells). Data are expressed as mean ± SEM, *p* \< 0.05.](pharmaceuticals-13-00059-g002){#pharmaceuticals-13-00059-f002}

![Ultra-performance liquid chromatography--electrospray ionization tandem mass spectrometry (UPLC--ESI--MS/MS) base peak chromatogram of the *E. lanceolatus* EA fraction. The peak numbers in this figure correspond to those used in [Table 2](#pharmaceuticals-13-00059-t002){ref-type="table"}.](pharmaceuticals-13-00059-g003){#pharmaceuticals-13-00059-f003}

![The chemical structures of some well-known identified compounds of biological importance from the *E. lanceolatus* EA fraction.](pharmaceuticals-13-00059-g004){#pharmaceuticals-13-00059-f004}

pharmaceuticals-13-00059-t001_Table 1

###### 

MIC and MBC (µg/mL) of *E. lanceolatus* extracts.

  Bacteria Strains            MIC and MBC (µg/mL) of *Echinops lanceolatus* Extracts \*   ATB                                                 
  --------------------------- ----------------------------------------------------------- -------- -------- -------- ---------------- ------- ---
  Gram-negative               *Salmonella enterica*                                       1024     512      512      256              1024    4
  *Escherichia coli*          \>1024                                                      \>1024   1024     1024     512              8       
  *Enterobacter cloacae*      1024                                                        1024     1024     512      1024             64      
  *Klebsiella pneumoniae*     1024                                                        1024     1024     \>1024   \>1024           \>256   
  *Pseudomonas aeruginosa*    \>1024                                                      \>1024   \>1024   1024     \>1024           \>256   
  *Acinetobacter baumannii*   \>1024                                                      \>1024   \>1024   1024     \>1024           256     
  Gram-positive               *Staphylococcus aureus*                                     1024     1024     512      512 (1024) ^B^   1024    4
  *Enterococcus faecalis*     \>1024                                                      \>1024   \>1024   \>1024   \>1024           256     

\* Each fraction tested in triplicate, at 1024 µg/mL. Reference antibiotic (ATB) Streptomycin (STR) tested at 256 µg/mL. MIC: Minimal Inhibitory Concentration; MBC: Minimal Bactericidal Concentration. ^B^: Bactericidal effect (MBC/MIC \< 4). MeOH: Methanol, Hex: *n*-Hexane, DCM: Dichloromethane, EA: Ethyl acetate, BuOH: *n*-Butanol.

pharmaceuticals-13-00059-t002_Table 2

###### 

Identified compounds from the *E. lanceolatus* EA fraction corresponding to the base peak chromatogram (BPC) in [Figure 3](#pharmaceuticals-13-00059-f003){ref-type="fig"}.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peak   Rt\     \[M-H\]^−^ (*m/z*)   MF                MS^2^ (*m/z*)                                                          Identification \*                       Ref
         (min)                                                                                                                                                         
  ------ ------- -------------------- ----------------- ---------------------------------------------------------------------- --------------------------------------- -------------------------------------
  1      1.16    117.0180             C~4~H~6~O~4~      117.0179, 99.0074, 73.0282                                             Succinic acid                           \[[@B9-pharmaceuticals-13-00059]\]

  2      1.22    191.0551             C~7~H~12~O~6~     191.0552, 173.0453, 127.0388, 93.0333, 85.0282                         Quinic acid                             \[[@B10-pharmaceuticals-13-00059]\]

  3      1.34    153.0181             C~7~H~6~O~4~      152.9947, 109.0282, 108.0201                                           Dihydroxybenzoic acid                   \[[@B11-pharmaceuticals-13-00059]\]

  4      1.53    167.0338             C~8~H~8~O~4~      167.0334, 152.0104, 123.0440, 108.0204, 91.0177                        Hydroxy-methoxy-benzoic acid isomer 1   \[[@B11-pharmaceuticals-13-00059]\]

  5      1.69    179.0339             C~9~H~8~O~4~      179.0553, 135.0442                                                     Dihydroxycinnamic acid isomer 1         \[[@B11-pharmaceuticals-13-00059]\]

  6      2.15    167.0338             C~8~H~8~O~4~      167.0334, 152.0104, 123.0440, 108.0204, 91.0177                        Hydroxy-methoxy-benzoic acid isomer 2   \[[@B11-pharmaceuticals-13-00059]\]

  7      2.44    179.0338             C~9~H~8~O~4~      179.0553, 135.0442                                                     Dihydroxycinnamic acid isomer 2         \[[@B11-pharmaceuticals-13-00059]\]

  8      3.08    163.0389             C~9~H~8~O~3~      163.0390, 120.0523, 119.0490                                           Coumaric acid isomer 1                  \[[@B11-pharmaceuticals-13-00059]\]

  9      3.29    163.0389             C~9~H~8~O~3~      163.0390, 120.0523, 119.0490                                           Coumaric acid isomer 2                  \[[@B11-pharmaceuticals-13-00059]\]

  10     4.58    187.0965             C~9~H~16~O~4~     187.0963, 125.0960, 97.0643                                            Nonanedioic acid                        \[[@B12-pharmaceuticals-13-00059]\]

  11     5.70    137.0231             C~7~H~6~O~3~      137.0232, 93.0333, 71.4599                                             3-Hydroxybenzoic acid                   \[[@B11-pharmaceuticals-13-00059]\]

  12     5.97    337.0924             C~16~H~18~O~8~    191.0552, 173.0444, 163.0389, 119.0489, 93.0332                        5-Coumaroylquinic acid                  \[[@B13-pharmaceuticals-13-00059]\]

  13     6.67    367.1027             C~17~H~20~O~9~    367.1055, 193.0497, 191.0553, 173.0444, 134.0361, 93.0330              5-Feruloyl quinic acid                  \[[@B14-pharmaceuticals-13-00059]\]

  14     7.67    515.1187             C~25~H~24~O~12~   353.0876, 191.0553, 179.0340, 161.0234, 135.0439, 93.0332, 85.0282     Dicaffeoylquinicacid isomer 1           \[[@B15-pharmaceuticals-13-00059]\]

  15     7.94    515.1186             C~25~H~24~O~12~   353.0874, 191.0552, 179.0340, 173.0445, 135.0439, 93.0332, 85.0282     Dicaffeoylquinicacid isomer 2           \[[@B15-pharmaceuticals-13-00059]\]

  16     8.29    515.1189             C~25~H~24~O~12~   515.1190, 353.0875, 191.0552, 179.0340, 173.0445, 161.0233, 135.0439   Dicaffeoylquinicacid isomer 3           \[[@B15-pharmaceuticals-13-00059]\]

  17     8.72    515.1189             C~25~H~24~O~12~   515.1190, 353.0875, 191.0552, 179.0340, 173.0445, 135.0439, 93.0333    Dicaffeoylquinicacid isomer 4           \[[@B15-pharmaceuticals-13-00059]\]

  18     9.04    287.0556             C~15~H~12~O~6~    287.0921, 259.0608, 243.0658, 201.0549, 177.0547, 151.0025, 125.0231   Dihydrokaempferol                       \[[@B16-pharmaceuticals-13-00059]\]

  19     9.33    433.1134             C~21~H~22~O~10~   433.1120, 313.0716, 271.0608, 177.0181, 151.0025, 119.0489, 107.0125   Naringenin-7-*O*-glucoside              \[[@B17-pharmaceuticals-13-00059]\]

  20     9.59    431.0977             C~21~H~20~O~10~   431.0980, 269.0441, 268.0373, 240.0422, 211.0392, 151.0025, 117.0333   Apigenin-7-*O*-glucoside                \[[@B18-pharmaceuticals-13-00059]\]

  21     10.53   177.0546             C~10~H~10~O~3~    177.0547, 162.0312, 145.0283, 133.0283, 123.0439, 121.0282, 117.0333   Coniferyl aldehyde                      \[[@B19-pharmaceuticals-13-00059]\]

  22     10.61   579.1503             C~27~H~32~O~14~   579.1474, 307.0825, 271.0610, 145.0283, 119.0490, 117.0334             Naringin                                \[[@B20-pharmaceuticals-13-00059]\]

  23     10.86   577.1346             C~27~H~30~O~14~   577.1351, 431.0982, 269.0453, 145.0284, 117.0333                       Rhoifolin                               \[[@B20-pharmaceuticals-13-00059]\]

  24     11.02   269.0451             C~15~H~10~O~5~    269.0451, 225.0551, 151.0025, 117.0332                                 Apigenin                                \[[@B21-pharmaceuticals-13-00059]\]

  25     11.12   329.2328             C~18~H~34~O~5~    329.2331, 311.2234, 229.1438, 211.1332, 171.1016, 139.1117, 99.0802    (-)-Pinellic acid                       /

  26     11.87   361.0818             C~20~H~26~O~6~    361.0820, 288.0636, 269.0451, 163.0390, 145.0283, 117.0333             (-)-Secoisolariciresinol                /

  27     13.09   293.2117             C~18~H~30~O~3~    293.2119, 265.2168                                                     13-Keto-9Z,11E-octadecadienoic acid     /

  28     13.45   295.2273             C~18~H~32~O~3~    295.2273, 251.2378                                                     13S-Hydroxyoctadecadienoic acid         /

  29     13.69   275.1647             C~17~H~24~O~3~    275.1648, 215.1434, 59.0125                                            Cyclandelate                            /

  30     14.17   277.2166             C~18~H~30~O~2~    277.2166                                                               α-Linolenic acid                        /

  31     14.63   255.2324             C~16~H~32~O~2~    255.2326                                                               Ethyl myristate                         /

  32     14.74   281.2479             C~18~H~34~O~2~    281.1389                                                               Oleic acid                              /
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MF: Molecular Formula. Rt: Retention time. Ref: Reference. \* Compounds corresponding to Peaks 1 to 24 were identified by comparison of the mass spectra with the available standards from databases (ChemSpider, mzCloud, mzVault, HDMB, and PubChem) and the literature data, whilst identification of Peaks 25 to 32 was only based on available standards from databases.

pharmaceuticals-13-00059-t003_Table 3

###### 

Gradient condition for UPLC--ESI--MS/MS analysis.

  Time    Phase A (5mM Ammonium Acetate, pH 9)   Phase B (50% ACN, 10mM Ammonium Acetate, pH 9)
  ------- -------------------------------------- ------------------------------------------------
  0.00    98%                                    2%
  1.50    98%                                    2%
  12.00   0%                                     100%
  14.00   0%                                     100%
  14.10   98%                                    2%
  16.00   98%                                    2%
